{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"FMUMUYFMLZGXJR-UHFFFAOYSA-N","prefName":"JTE-7-31","symbol":"JTE-7-31","iupacName":"2-[2-(4-hydroxyphenyl)ethyl]-5-methoxy-4-(pentylamino)-3H-isoindol-1-one","aliases":["JTE 7-31","7MV5OX2NX0"],"cas":"194358-72-0","pubchemCid":"19363402","chebiId":null,"smiles":"CCCCCNC1=C(C=CC2=C1CN(C2=O)CCC3=CC=C(C=C3)O)OC","molecularFormula":"C22H28N2O3","molecularWeight":368.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/19363402"}},"classification":{"family":"ecs_tool","familyLabel":"ECS modulator (research)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (research tool)","summaryFr":"No known biosynthetic pathway: a chemically synthesised molecule of the isoindolinone family.","originNote":"Fully synthetic molecule, developed by Japan Tobacco in research on peripheral cannabinoid receptors. No source consulted reports it in a plant.","discovered":""},"pharmacology":{"summaryFr":"JTE-7-31 is a synthetic ligand of cannabinoid receptors with an isoindolinone structure: 2-[2-(4-hydroxyphenyl)ethyl]-5-methoxy-4-(pentylamino)isoindolin-1-one. Described in patents filed by Japan Tobacco in 1996 and 1997, it is presented by US patent 6 017 919 (published in 2000) as one of the compounds of a series of selective ligands of peripheral cannabinoid receptors. That patent reports a Ki of 0.088 nM at CB2 (rat splenocytes) and 11 nM at CB1 (rat cerebellum), a ratio of 125. It also reports that, in mice, the compound reduces carrageenan-induced paw oedema, with a median effective dose of 0.012 mg/kg orally. No human study and no pharmacokinetic profile are published in the sources consulted, and the agonist or antagonist nature of the molecule is not measured there.","receptorSummaryFr":"High affinity for the CB2 receptor, with a Ki of 0.088 nM measured on rat splenocytes, and clearly lower affinity for CB1, with a Ki of 11 nM measured on rat cerebellum. The selectivity ratio is 125 in favour of CB2 in this assay. For receptors, the patent reports only binding measurements: no functional assay shows whether the molecule activates or blocks the receptor. The English-language Wikipedia (tertiary pointer) describes it as an agonist, but this claim rests on no primary source consulted.","binding":[{"target":"CB2","efficacy":"modulator","relativeActivity":95,"reported":"Ki 0,088 nM, splénocytes de rat (Inaba et coll., brevet US 6 017 919, 2000)","confidence":"medium"},{"target":"CB1","efficacy":"modulator","relativeActivity":85,"reported":"Ki 11 nM, cervelet de rat (Inaba et coll., brevet US 6 017 919, 2000)","confidence":"medium"}],"references":[{"label":"Inaba et coll., Composés et usage pharmaceutique (brevet US 6 017 919, Japan Tobacco), 2000","pmid":null,"doi":null,"url":"https://patents.google.com/patent/US6017919A/en"},{"label":"Arrêté du 14 octobre 2019 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000039223507"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (tableaux de la Convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, notice du composé JTE-7-31 (CID 19363402)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/19363402"},{"label":"Wikipedia, notice JTE 7-31 (repère tertiaire)","pmid":null,"doi":null,"url":"https://en.wikipedia.org/wiki/JTE_7-31"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":6},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":3},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":4},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":3},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":2}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"controlled-named","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised control measure at European Union level was found in the sources consulted for this molecule: its status falls under national legislation. It is not listed in the INCB Green List 2026, which reproduces the schedules of the 1971 Convention.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"JTE-7-31 is named in Annex IV of the French list of narcotics, by the order of 14 October 2019 amending the order of 22 February 1990. This annex covers psychoactive substances classed in France or the European Union but not classed under the international conventions. Its use, possession and supply therefore fall under the narcotics regime.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Inaba et coll., Composés et usage pharmaceutique (brevet US 6 017 919, Japan Tobacco), 2000","pmid":null,"doi":null,"url":"https://patents.google.com/patent/US6017919A/en"},{"label":"Arrêté du 14 octobre 2019 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000039223507"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (tableaux de la Convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, notice du composé JTE-7-31 (CID 19363402)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/19363402"},{"label":"Wikipedia, notice JTE 7-31 (repère tertiaire)","pmid":null,"doi":null,"url":"https://en.wikipedia.org/wiki/JTE_7-31"}],"meta":{"slug":"jte-7-31","url":"https://en.phytogrammes.com/wiki/jte-7-31","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}